Swiss stocks - Factors to watch on July 13

ZURICH, July 13 (Reuters) - Swiss stocks are seen opening a bit firmer on Tuesday, in line with other markets across Europe as confidence rises in the wake of forecast-beating figures from U.S. group Alcoa (AA.N).

The Swiss blue-chip index SMI .SSMI was indicated to open 2 points higher at 6,231 points, premarket data provided by bank Clariden Leu showed. CLPRE

The following are some of the main factors expected to affect Swiss stocks on Tuesday:

NESTLE (NESN.VX)

Luxury cosmetics group L'Oreal, in which Nestle owns a 30 percent stake, posted higher revenue in the second quarter helped by emerging markets and positive currency effects, confirming a recovery in consumer spending that started earlier this year.

For related news, click on [NESN.VX]

UBS (UBSN.VX)

UBS, battling hard to keep its star U.S. brokers in place after a tax evasion scandal, says it has turned the tide of defections.

For related news, click on [UBSN.VX]

NOVARTIS (NOVN.VX)

The American Society of Clinical Oncology issued new guidelines on Monday for the use of hormone-based breast cancer drugs called aromatase inhibitors.

Aromatase inhibitors include anastrozole, made by AstraZeneca (AZN.L) under the brand name Arimidex, exemestane, made by Pfizer Inc (PFE.N), under the brand name Aromasin and Novartis's Femara or letrozole.

For related news, click on [NOVN.VX]

ECONOMY [M-CH]

* Swiss producer and import price data are due at 0715 GMT.ECONCH

COMPANY STATEMENTS [CNR-CH]

* Partners Group's (PGHN.S) client demand results in inflows of 3.0 billion Sfr (EUR 2.1 billion) during the first half of 2010.

Partners Group is increasing its guidance to EUR 4 billion in assets raised for the full year 2010, which translates into 5.0-5.5 billion Sfr. [PGHN.S]

* Addex Pharmaceuticals Ltd. (ADXN.S) announced today that its preclinical drug candidate ADX71943 was effective in a model of osteoarthritis pain.[ADXN.S]

* Human Genome Sciences, Inc. and Lonza (LONN.VX) today announced an agreement for the future commercial supply of BENLYSTA, which is currently under regulatory review in the United States and Europe as a potential new treatment for systemic lupus erythematosus (SLE).

* Nobel Biocare (NOBN.VX) received notification that UBS had a change to the composition of its group per 6 July 2010 and held 4.11 percent of the registered share capital of Nobel Biocare at that time.[NOBN.VX]

* Roche (ROG.VX) obtains co-exclusive license to develop PCR assays detecting mutations in the PI3K oncogene. [ROG.VX]

* ALTIN (ALTN.S) announces portfolio holdings as at 1st July 2010. [ALTN.S]

EQUITY RESEARCH [CH-RCH]

* Citigroup lowers ABB (ABBN.VX) price target to 25 Sfr from 26.30 Sfr

* JP Morgan raises SGS (SGSN.VX) price target to 1,524 Sfr from 1,507 Sfr

* BOFA Merrill raises SGS price target to 1,650 Sfr from 1,500 Sfr

* Goldman Sachs raises Nestle (NESN.VX) price target to 61.80 Sfr from 56.30 Sfr

* Goldman Sachs raises Aryzta (ARYN.S) price target to 38.90 Sfr from 37 Sfr

FOR COMPANIES TRADING EX-DIVIDEND, PLEASE CLICK ON:

.EX.S for all Swiss stocks

.EXSMI.S for blue chips

.EXNSMI.S for other stocks